# IMCODE003 (NCT05968326)

> A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

No report yet. It can be ordered.

- Drugs tested: autogene cevumeran plus atezolizumab
- Indication: resected pancreatic ductal adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05968326
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Genentech, Inc.
- Conditions: Adenocarcinoma, Pancreatic Ductal
- Interventions: Autogene cevumeran; Atezolizumab; mFOLFIRINOX
- Enrollment: 260
- Primary outcome: Disease Free Survival (DFS)

## Indexed commentary on IMCODE003 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=imcode003-nct05968326